An ultrasound-assisted manganese dioxide vaccine delivery system and its preparation method and application

Through the ultrasonic-assisted manganese dioxide vaccine delivery system, hollow mesoporous manganese dioxide nanospheres and chitooligosaccharides loaded egg albumin is used to solve the problem of low delivery efficiency of mucosal vaccines, significantly improve the immune response effect of nasal vaccines, and promote the promotion of Mucosal immune response and antigen delivery.

CN115054685BActive Publication Date: 2024-11-05HUNAN UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210582702.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-26
Publication Date
2024-11-05
Estimated Expiration
2042-05-26

AI Technical Summary

Technical Problem

The delivery efficiency of existing mucosal vaccines is inefficient and cannot effectively induce mucosal immune responses, especially in the nasal delivery route, fast antigen degradation, low immune cell uptake rate, and poor antigen stability, resulting in insufficient vaccine development.

Method used

Using an ultrasonic-assisted manganese dioxide vaccine delivery system, the shell oligosaccharides are coated with hollow mesoporous manganese dioxide nanospheres and loaded with ovalbumin. Ultrasound waves are used to promote antigens to penetrate the mucosal surface layer and cell membranes to enhance immune response.

Benefits of technology

It significantly improves the mucosal delivery efficiency and immune response effect of antigen, promotes the recruitment of dendritic cells and macrophages in nasal mucosal tissues, enhances the level of secreted IgA antibodies and cytokine secretion, and induces stronger mucosal immune response .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115054685B_ABST
    Figure CN115054685B_ABST
Patent Text Reader

Abstract

The present invention discloses an ultrasound-assisted manganese dioxide vaccine delivery system and its preparation method and application. The preparation method of the vaccine delivery system comprises the following steps: reacting tetraethyl orthosilicate, concentrated ammonia water and ethanol to obtain SiO2 nanoparticles, then reacting the nanoparticles with potassium permanganate to obtain mesoporous MnO2-coated SiO2, then further reacting the mesoporous MnO2-coated SiO2 with Na2CO3 to obtain hollow mesoporous MnO2 nanoparticles, then reacting the nanoparticles with a chitosan oligosaccharide solution to obtain a MnO2@COS suspension, and finally mixing and incubating MnO2@COS with an ovalbumin solution to obtain the vaccine delivery system. The vaccine delivery system prepared by the present invention can promote the cross-mucus delivery of the vaccine preparation and the penetration of the surface layer of the nasal mucosa under the assistance of ultrasound, and enhance the immune response induced by the mucosal vaccine. Therefore, it has important application value in the field of mucosal vaccine treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedical materials, and particularly relates to an ultrasound-assisted manganese dioxide vaccine delivery system and a preparation method and application thereof. Background Art

[0002] It is estimated that 70% of pathogens invade the host through mucosal sites. The mucosal immune system, as the first immune barrier of the human body, has a higher antibody concentration than other tissues in the body, and resists more than 90% of potential pathogens. To resist pathogens that invade through mucosal sites, mucosal vaccination is the best means. However, to date, the vast majority of infectious disease vaccines approved for marketing are administered through non-mucosal routes. These vaccines only induce effective systemic immune responses, but cannot induce effective mucosal immune responses. The reason is that during vaccination at mucosal sites, the delivery efficiency is low due to the fact that vaccine preparations are easily cleared quickly and are difficult to pass through the mucosal surface, and cannot induce effective mucosal immune responses. To this end, researchers have adopted various strategies to enhance the effect of mucosal vaccine delivery.

[0003] At present, the development of mucosal vaccines can be roughly divided into two categories: one is to use attenuated or inactivated viruses and bacteria as antigen carriers, and enhance the delivery effect of mucosal vaccines through the autonomous invasion ability of these pathogens, such as adenovirus vectors and lactic acid bacteria vectors; the other is to use biomaterials as carriers and utilize their unique physical and chemical properties (such as electrostatic adsorption) to enhance the transmucosal delivery of vaccines, such as liposomes and squalene nanoemulsions. However, at present, the number of safe and effective mucosal vaccines is extremely small, far from enough to meet the widespread clinical demand for mucosal vaccines.

[0004] The delivery route is an important factor affecting the effectiveness of mucosal vaccination, among which oral delivery and nasal delivery are the most common. However, oral delivery faces multiple challenges, especially the proteolytic enzymes in the gastrointestinal tract and the acidic pH environment that easily degrade antigens. Compared with other mucosal vaccine delivery routes, the degree of antigen degradation is greatly reduced in nasal delivery, and a large number of immune cells are distributed in the nasal cavity, and the surface layer of the nasal mucosa is relatively easy to penetrate. In addition, nasal delivery is a needle-free injection, and non-technically skilled personnel can perform immunization. Despite the above-mentioned multiple advantages of nasal delivery, only a few nasal vaccines have been approved for marketing. This is because there are still many problems in the development of nasal vaccines: the uptake rate of soluble antigens by nasal immune cells is low, the antigens are easily cleared quickly by cilia in the nasal cavity, resulting in a short residence time, poor antigen stability, and insufficient antigen delivery.

[0005] Ultrasound is a mechanical sound wave that vibrates periodically and has been widely used in medical imaging diagnosis. It is also used for drug delivery, including chemotherapy drugs, hydrocortisone, salicylic acid, oligonucleotides, insulin and vaccines.

[0006] In recent years, the application of MnO2 nanoparticles as vaccine carriers and adjuvants has attracted widespread attention. MnO2 materials can be degraded into harmless water-soluble Mn 2+ , so it has good biocompatibility. Secondly, MnO2 nanoparticles can load and deliver antigens and have a carrier function. In addition, the Mn produced by the degradation of MnO2 2+ It has an adjuvant effect and can enhance the body's immune response. However, MnO2 nanoparticles are negatively charged and have electrostatic repulsion with antigens and mucosal surfaces with the same charge, which is not conducive to antigen loading and transmucosal delivery. Summary of the invention

[0007] The primary purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and to provide a method for preparing an ultrasound-assisted manganese dioxide vaccine delivery system.

[0008] Another object of the present invention is to provide an ultrasound-assisted manganese dioxide vaccine delivery system prepared by the method.

[0009] Another object of the present invention is to provide an application of the ultrasound-assisted manganese dioxide vaccine delivery system.

[0010] The purpose of the present invention is achieved through the following technical solutions:

[0011] A method for preparing an ultrasound-assisted manganese dioxide vaccine delivery system is obtained by coating chitosan oligosaccharide (COS) with hollow mesoporous manganese dioxide nanospheres (MnO2) and loading ovalbumin (OVA), specifically comprising the following steps:

[0012] (1) adding tetraethyl orthosilicate, concentrated ammonia water and anhydrous ethanol to water, stirring for reaction, collecting the precipitate by centrifugation after the reaction is completed, washing and freeze-drying to obtain SiO2 nanoparticles;

[0013] (2) mixing the potassium permanganate aqueous solution and the SiO2 nanoparticles uniformly with ultrasound and then stirring to react, collecting the precipitate by centrifugation after the reaction is completed, washing, and resuspending in water to obtain a mesoporous MnO2-coated SiO2 suspension;

[0014] (3) adding the mesoporous MnO2-coated SiO2 suspension to a Na2CO3 aqueous solution, stirring the reaction at 60±5°C, collecting the precipitate by centrifugation after the reaction is completed, washing, and freeze-drying to obtain hollow mesoporous MnO2 nanoparticles;

[0015] (4) mixing the hollow mesoporous MnO2 nanoparticles and chitosan oligosaccharide (COS) solution by ultrasonic mixing and stirring, collecting the precipitate by centrifugation after the reaction is completed, washing, and resuspending in water to obtain a MnO2@COS suspension;

[0016] (5) The MnO2@COS suspension and the ovalbumin (antigen) solution are mixed and incubated at room temperature for 3 to 6 hours to obtain the vaccine preparation MnO2@COS@OVA particles, namely the ultrasound-assisted manganese dioxide vaccine delivery system.

[0017] The concentration of the concentrated ammonia water described in step (1) is 28% by mass.

[0018] The volume ratio of ethyl orthosilicate, concentrated aqueous ammonia, anhydrous ethanol and water in step (1) is 9:18:124:49.

[0019] The water described in step (1) is deionized water.

[0020] The stirring reaction conditions in step (1) are: stirring at 400-600 rpm for 2-3 h; preferably: stirring at 500 rpm for 2 h.

[0021] The centrifugal conditions in steps (1), (2), (3) and (4) are: centrifugation at 8000-10000 rpm for 8-12 min; preferably: centrifugation at 8000-10000 rpm for 10 min.

[0022] The washing in step (1) is performed by alternating anhydrous ethanol and deionized water; preferably, the washing is performed by alternating anhydrous ethanol and deionized water four times.

[0023] The amount of potassium permanganate used in step (2) is calculated based on 7.5 mg of potassium permanganate per mg of SiO2 nanoparticles.

[0024] The concentration of the potassium permanganate aqueous solution described in step (2) is preferably 0.4 to 0.5 g / mL.

[0025] The ultrasonic conditions described in steps (2) and (4) are: frequency 1 MHZ, power 6 W, time 5 minutes: work for 5 seconds and stop for 5 seconds.

[0026] The stirring reaction conditions in step (2) are: stirring at 400-600 rpm for 5-8 h; preferably: stirring at 500 rpm for 6 h.

[0027] The washing in steps (2) and (3) is performed using deionized water; preferably, the washing is performed 3 times using deionized water.

[0028] The concentration of the Na2CO3 aqueous solution described in step (3) is preferably 2 mol / L.

[0029] The amount of Na2CO3 used in step (3) is calculated based on the molar ratio of SiO2 to Na2CO3 in the reaction system of 1:10.

[0030] The stirring reaction conditions in step (3) are: stirring at 100-200 rpm for 10-14 h; preferably: stirring at 100 rpm for 12 h.

[0031] The chitosan oligosaccharide (COS) described in step (4) has a degree of polymerization of 2 to 20 and a molecular weight of ≤3200Da.

[0032] The amount of chitosan oligosaccharide used in step (4) is calculated based on 1 mg of chitosan oligosaccharide per mg of hollow mesoporous MnO2 nanoparticles.

[0033] The stirring reaction conditions in step (4) are: stirring at 100-200 rpm for 1-3 h; preferably: stirring at 100 rpm for 2 h.

[0034] The washing in step (4) is performed using deionized water; preferably, the washing is performed using deionized water 2 to 3 times.

[0035] The mass ratio of MnO2@COS to ovalbumin described in step (5) is 30-50:3, preferably 10:1.

[0036] The room temperature incubation time in step (5) is preferably 3 h.

[0037] The concentration of the ovalbumin solution described in step (5) is preferably 3 mg / mL, wherein the solvent used to prepare the ovalbumin solution is PBS buffer or physiological saline (preferably PBS buffer).

[0038] The incubation in step (5) is carried out in a shaking incubator, and the rotation speed is preferably 20 rpm.

[0039] An ultrasound-assisted manganese dioxide vaccine delivery system is prepared by any of the methods described above.

[0040] The application of the ultrasound-assisted manganese dioxide vaccine delivery system in the preparation of mucosal vaccine preparations.

[0041] The ultrasound-assisted manganese dioxide vaccine delivery system can promote mucosal immune responses, including Th1 type immune responses (Th1 cell-mediated cellular immune responses) and Th2 type immune responses (Th2 cell-mediated cellular immune responses).

[0042] The vaccination route of the vaccine preparation is mucosal administration; preferably nasal mucosal administration (nasal drops administration).

[0043] The vaccine preparation needs to be ultrasonically treated in the nasal cavity after administration, and the ultrasonic-assisted conditions are preferably: frequency 1 MHZ, power 6 W, time 5 minutes: work for 5 seconds and stop for 5 seconds; the ultrasonic treatment can promote the transmucus delivery of the vaccine preparation and the penetration of the surface layer of the nasal mucosa, and can promote the recruitment of dendritic cells (DCs) and macrophages in the nasal mucosal tissue, and the ultrasonic treatment can increase the level of secretory IgA antibodies in the nasal mucosa and genital mucosa, and promote the secretion of cytokines (IFN-γ and IL-6) by spleen cells in vitro.

[0044] The vaccine preparation was stored at 4°C.

[0045] Compared with the prior art, the present invention has the following advantages and effects:

[0046] 1. The present invention uses ultrasound to promote the nasal mucosal presentation of vaccine preparations to enhance the immune response induced by mucosal vaccines: Ultrasound is a mechanical sound wave with periodic vibrations, which has been widely used in medical imaging diagnosis and is also used for drug delivery. Vaccine preparations can move under the action of ultrasound, which can be used to promote the penetration of antigens through the mucosal surface. Ultrasound can also change the permeability of cell membranes, which is expected to enhance the efficiency of antigen entry into cells. In addition, ultrasound can induce inflammatory responses, play an adjuvant role in mucosal immune responses, and promote the recruitment of dendritic cells (DCs) and macrophages, providing an important basis for the use of ultrasound to improve mucosal vaccine immunization.

[0047] 2. MnO2 material can be degraded into harmless water-soluble Mn2 in the body + , has good biocompatibility, Mn2 + It can enhance the immune stimulation effect, but it is fragile and has weak antigen loading capacity. In addition, MnO2 nanoparticles are negatively charged and have electrostatic repulsion with antigens and mucosal surfaces with the same charge, which is not conducive to antigen loading and transmucosal delivery. To overcome this shortcoming, the present invention coats COS, a chitosan degradation product with good biocompatibility and biodegradability, on the surface of MnO2 to construct MnO2@COS. The electrostatic attraction between COS and the mucosal surface prolongs the vaccine residence time. COS can also open the intercellular spaces of the mucosal surface, promote mucosal absorption, and improve the mucosal delivery efficiency of the antigen. On this basis, the obtained MnO2@COS nanoparticles are further physically adsorbed with a model antigen, ovalbumin (OVA), to construct a nanoparticle vaccine preparation MnO2@COS@OVA.

[0048] 3. The present invention applies ultrasound to the nasal mucosal delivery of vaccine preparations for the first time. Ultrasonic treatment can promote antigen presentation and the recruitment of dendritic cells (DCs) and macrophages in nasal mucosal tissue. Under the assistance of ultrasound, MnO2@COS@OVA particles can promote the maturation of DCs in vivo and in vitro, and promote the production of central memory T cells and effector memory T cells in vivo, and promote the secretion of cytokines by spleen cells in vitro. Ultrasonic treatment significantly increases the level of secretory IgA antibodies in the nasal mucosa and genital mucosa of experimental mice. Therefore, it has important application value in the field of vaccine therapy.

[0049] 4. The ultrasound-assisted vaccine delivery system (MnO2@COS@OVA+US) constructed by the present invention has the following advantages for improving nasal mucosal response: (1) Ultrasound can promote the penetration of vaccine preparations into the surface layer of the nasal mucosa; (2) Ultrasound can promote the recruitment of DCs and macrophages in the nasal mucosal tissue; (3) The source of materials used to synthesize MnO2@COS is abundant, the preparation method is simple, and the biosafety is good; (4) COS coated on the surface of MnO2 can open the intercellular spaces of the mucosal surface layer, promote mucosal absorption, and improve the mucosal delivery efficiency of antigens; (5) Under the assistance of ultrasound, MnO2@COS@OVA particles can promote the maturation of DCs in vivo; (6) The ultrasound-assisted vaccine delivery system can induce higher levels of antigen-specific IgA antibody titers, IFN-γ, TNF-α, IL-4 and IL-6, and therefore has important application value in the field of mucosal vaccines.

[0050] 5. The present invention found that when the MnO2@COS@OVA vaccine preparation is inoculated into the body with the assistance of ultrasound, ultrasound can promote the penetration of the vaccine preparation into the surface layer of the nasal mucosa, induce a stronger mucosal immune response, and promote the production of central memory T cells and effector memory T cells in the body, inducing a long-term and effective immune response. Therefore, this research work provides a new perspective for the development of new mucosal vaccines. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 These are the TEM images of MnO2, MnO2@COS and MnO2@COS@OVA.

[0052] Figure 2 It is the Zeta potential diagram of MnO2, MnO2@COS and MnO2@COS@OVA.

[0053] Figure 3 This is a diagram showing the effect of in vitro simulated ultrasound treatment on the transmucus delivery of vaccine formulations (MnO2@COS@OVA, MnO2@COS@OVA+US).

[0054] Figure 4This is a graph showing the effect of ultrasonically treated vaccine preparations on antigen presenting cells (APCs) in nasal mucosal tissue (in the graph, red fluorescence is the number of DCs, green fluorescence is the number of macrophages, and blue fluorescence is the total number of cells).

[0055] Figure 5 It is the result of immunohistochemical staining; A is the immunohistochemical staining of nasal mucosal tissue of three groups of animals (n=3), OVA, MnO2@COS@OVA, and MnO2@COS@OVA+US (in the figure: the upper part is the overall picture; the lower part is the enlarged picture of the part circled by red squares, indicating the amount of OVA antigen delivered); B is the ratio of IOD to Area of ​​the immunohistochemical picture (that is, the ratio of the amount of OVA (brown) to the tissue area).

[0056] Figure 6 This is a graph showing the results of measuring the titer of IgA antibodies secreted from the nasal cavity.

[0057] Figure 7 This is a graph showing the results of measuring the titer of IgA antibodies secreted by the reproductive tract.

[0058] Figure 8 This is a diagram showing the results of an IFN-γ secretion experiment.

[0059] Fig. 9 This is a graph showing the results of an IL-6 secretion experiment. DETAILED DESCRIPTION

[0060] The present invention will be described in further detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The test methods for which specific experimental conditions are not specified in the following examples are usually carried out according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present invention can be obtained commercially.

[0061] The ovalbumin (OVA) involved in the examples of the present invention was purchased from Sigma.

[0062] The chitosan oligosaccharide (COS) involved in the embodiments of the present invention has a polymerization degree of 2 to 20 and a molecular weight of ≤3200 Da, and was purchased from Jinan Haidebei Biomaterial Co., Ltd.

[0063] Example 1 Preparation of ultrasound-assisted manganese dioxide vaccine delivery system and its application in promoting mucosal immune response

[0064] 1. MnO2@COS@OVA vaccine preparation is prepared by the following steps:

[0065] (1) 4.5 mL of tetraethyl orthosilicate, 9 mL of 28% (mass fraction) concentrated ammonia water, 62 mL of anhydrous ethanol, and 24.5 mL of deionized water were mixed and stirred at room temperature for 2 h (500 rpm). The mixture was centrifuged at 8000 rpm for 10 min, and the precipitate was collected, washed twice with anhydrous ethanol and deionized water, and freeze-dried to obtain SiO2 nanoparticles.

[0066] (2) Under the action of ultrasound (ultrasonic frequency of 1 MHZ, power of 6 W, ultrasonic time of 5 minutes: work for 5 seconds and stop for 5 seconds), add a potassium permanganate aqueous solution containing 300 mg of potassium permanganate (prepared by dissolving 4.5 g of potassium permanganate in 90 mL) to a SiO2 suspension containing 40 mg of SiO2 nanoparticles (prepared by adding 600 mg of SiO2 nanoparticles into 10 mL), and continue stirring at room temperature for 6 hours (500 rpm). Centrifuge at 10000 rpm for 10 minutes, collect the precipitate, wash it with deionized water 3 times, and then add it to 10 mL of deionized water to obtain a mesoporous MnO2-coated SiO2 suspension.

[0067] (3) The mesoporous MnO2-coated SiO2 suspension obtained in step (2) was added to a 2M sodium carbonate aqueous solution (containing 10.6 g sodium carbonate, 50 mL of the reaction system used in the experiment), and stirred at 60°C for 12 h (100 rpm). Centrifuged at 10000 rpm for 10 min, the precipitate was collected, washed three times with deionized water, and freeze-dried to obtain hollow mesoporous MnO2 nanoparticles (abbreviated as MnO2).

[0068] (4) Under the action of ultrasound (ultrasonic frequency of 1 MHZ, power of 6 W, ultrasonic time of 5 minutes: 5 seconds of work and 5 seconds of rest), 2 mL of the suspension of hollow mesoporous MnO2 nanoparticles (2 mg / mL) was added to 4 mL of COS solution (1 mg / mL) and stirred at room temperature for 2 h (100 rpm). After centrifugation at 8000 rpm for 10 min, the precipitate was collected, washed twice with deionized water, and then added to 10 mL of deionized water to obtain a MnO2@COS suspension.

[0069] (5) The MnO2@COS suspension (containing 3 mg MnO2@COS) was mixed with the OVA solution (containing 300 μg OVA, i.e., the concentration of the OVA solution was 3 mg / mL, the dosage was 100 μL, and the solvent was PBS buffer) and incubated on a shaker (20 rpm) at room temperature for 3 h to obtain the vaccine preparation MnO2@COS@OVA particles.

[0070] The morphology of the MnO2, MnO2@COS and MnO2@COS@OVA nanoparticles prepared in steps (3) to (5) was observed using a transmission electron microscope (TEM). Figure 1 As shown: All three particles have a hollow mesoporous spherical structure with a particle size of about 350 nm.

[0071] 2. Preparation of other vaccine preparations

[0072] OVA was used as the model antigen and PBS buffer was used as the solvent to prepare 1 mL of OVA (containing 300 μg). A vaccine preparation was prepared with aluminum adjuvant and OVA (incubated at room temperature or on a 20 rpm shaker for 3 to 6 hours; this experiment chose to incubate on a shaker at room temperature for 3 hours) as a positive control (without MnO2@COS), and a 300 μg / mL OVA solution (prepared with PBS) was used as a negative control. The vaccine preparation was stored at 4°C. Vaccines with different formulations were prepared according to Table 1.

[0073] Table 1 Vaccine formulations for nasal / subcutaneous injection

[0074] Group <![CDATA[MnO2@COS(mg)]]> Ovalbumin (μg) PBS (μL) Negative control (OVA) 0 300 1000 <![CDATA[MnO2@COS@OVA-SC]]> 3 300 1000 <![CDATA[MnO2@COS@OVA]]> 3 300 1000 <![CDATA[MnO2@COS@OVA+US]]> 3 300 1000 Alum / OVA Aluminum adjuvant (500μL) 300 500

[0075] Note: In the table, "SC" means subcutaneous inoculation; "US" means ultrasonic treatment.

[0076] 3. Zeta potential detection

[0077] The zeta potential of different particles (MnO2, MnO2@COS, MnO2@COS@OVA) was measured using a Malvern laser nanoparticle size analyzer, and the test sample concentration was 0.05 mg / mL.

[0078] The results are as follows Figure 2 As shown: the Zeta potential of MnO2 is -34.80±0.36mV, the Zeta potential of MnO2@COS is 14.30±0.81mV, and the Zeta potential of MnO2@COS@OVA is -1.21±0.43mV. The results show that COS is successfully coated on the surface of MnO2, converting its surface negative charge into positive charge, which is more conducive to OVA loading.

[0079] Effect of ultrasonic treatment on transmucus delivery of MnO2@COS@OVA particles

[0080] (1) We dissolved 2.5 mg of mucin (purchased from Shanghai Yuanye Biotechnology Co., Ltd.) in 10 mL of deionized water to obtain a mucin solution to simulate nasal mucus.

[0081] (2) 0.02 g of sodium alginate and 0.05 g of calcium chloride were dissolved in 10 mL of deionized water to prepare a hydrogel. The resulting mucin solution was applied to the surface of the hydrogel to simulate the surface of the nasal mucosa.

[0082] (3) 200 μL of MnO2@COS@OVA suspension (1 mg / mL) was added to two groups (MnO2@COS@OVA group and MnO2@COS@OVA+US group), each of which consisted of 4 mL of mucin solution and 5 mL of hydrogel; the MnO2@COS@OVA group was left naturally for 5 minutes, and the MnO2@COS@OVA+US group was ultrasonically treated for 5 minutes (ultrasonic frequency was 1 MHZ, power was 6 W, and ultrasonic time was 5 minutes: work for 5 seconds and stop for 5 seconds). Subsequently, the two groups were rinsed with deionized water twice to remove mucin and free particles on the hydrogel surface. The retention of particles in the two groups of hydrogels was observed under a microscope.

[0083] The results are as follows Figure 3 As shown: Compared with the control group (MnO2@COS@OVA group), ultrasound treatment (MnO2@COS@OVA+US group) significantly promoted the transmucosal delivery of the vaccine formulation. This result indicates that ultrasound treatment is expected to enhance the transmucosal delivery of vaccine formulations in vivo.

[0084] 5. Tissue section observation of nasal mucosa tissue

[0085] Fifteen 4-6 week old C57BL / 6 female mice (Beijing Huafukang) were randomly divided into five groups (PBS, PBS+US, OVA, MnO2@COS@OVA, MnO2@COS@OVA+US), and different vaccine preparations and treatments were administered by intranasal route (40 μL vaccine preparation was administered to each mouse, the formula is shown in Table 1); among them, the PBS, OVA and MnO2@COS@OVA groups were directly administered by intranasal route, while the PBS+US and MnO2@COS@OVA+US groups were treated with ultrasound in the nasal cavity of the experimental animals after intranasal administration (ultrasonic frequency of 1 MHZ, power of 6 W, ultrasound time of 5 minutes: 5 seconds of work and 5 seconds of rest). After 24 hours, the nasal tissue was surgically removed. The obtained tissue was fixed with 4% paraformaldehyde for 48 hours and decalcified for 30 days. The decalcified tissue was embedded in paraffin and sliced. The sections were subjected to immunofluorescence staining (fluorescent labeled antibody reagents (purchased from Wuhan Saiweier Biotechnology Co., Ltd.): Cy3-anti-CD11c, FITC-anti-CD68). Dendritic cells (DCs) and macrophage recruitment in nasal mucosal tissue were observed under a microscope. In addition, three groups of sections containing OVA were subjected to immunohistochemical staining and observed under a microscope to analyze the efficiency of OVA antigen delivery.

[0086] Effects of ultrasonic treatment of vaccine preparations on APCs (DCs and macrophages are both antigen presenting cells (APCs)) in nasal mucosal tissues Figure 4As shown in the figure, the number of DCs and macrophages in the PBS+US group was greater than that in the PBS group. This indicates that ultrasound treatment can promote the recruitment of DCs and macrophages. In addition, compared with the OVA group and the MnO2@COS@OVA group, the number of DCs and macrophages in the MnO2@COS@OVA+US group was greater. This experiment shows that ultrasound treatment can promote the recruitment of DCs and macrophages in the surface tissue of the nasal mucosa, which helps to enhance further immune responses.

[0087] Immunohistochemical staining results Figure 5 As shown: The content of OVA in the nasal mucosa of the MnO2@COS@OVA+US group was significantly higher than that of the OVA group. This experiment shows that the vaccine preparation treated with ultrasound can significantly promote the penetration of the vaccine preparation into the mucosal surface.

[0088] VI. Mouse immunization scheme and determination of various immune indicators

[0089] According to the formula in Table 1, 25 C57BL / 6 female mice (4-6 weeks old, Beijing Huafukang) were divided into 5 groups; 4 of them were intranasal groups: OVA group, aluminum adjuvant group (Alum@OVA group), MnO2@COS@OVA group, and MnO2@COS@OVA+US group. Each mouse was administered by intranasal route (40μL vaccine preparation), and the MnO2@COS@OVA+US group was subjected to ultrasonic treatment of the nasal cavity of the experimental animals for 5 minutes after intranasal administration (ultrasonic frequency of 1MHZ, power of 6W, ultrasonic time of 5 minutes: 5 seconds of work and 5 seconds of stop); the remaining group was a subcutaneous vaccination group (MnO2@COS@OVA-SC group), and each mouse was administered by subcutaneous route (40μL vaccine preparation). The OVA content in the vaccine preparations of the 5 groups was 300μg / mL. A total of three vaccinations were performed, with the first vaccination recorded as day 0, and booster immunizations on days 7 and 11 respectively. The mice were killed 4 days after the last vaccination, and spleen cells, blood, nasal lavage fluid, and reproductive tract lavage fluid were collected.

[0090] (1) Determination of IgG antibody titer

[0091] The titer of OVA-specific antibodies in the serum of experimental mice was detected by enzyme-linked immunosorbent assay (ELISA). First, the antigen OVA solution (10 μg / mL) was prepared with carbonate buffer (0.1 M, pH 9.6) and added to a 96-well plate (100 μL / well) and coated overnight at 4°C. The next day, the plate was washed three times with PBS (PBST) containing 0.05% (v / v) Tween-20, and a blocking solution (PBST solution containing 2% (v / v) bovine serum albumin, 200 μL / well) was added, and the plate was placed in a microplate shaking incubator for incubation for 1 hour (37°C, 400 rpm). Subsequently, the plate was washed three times with PBST, and the gradient diluted serum sample (100 μL / well) was added, repeated three times, and incubated for another 2 hours. Subsequently, the plate was washed three times with PBST and tapped until there was no residual liquid in the well plate. Next, add horseradish peroxidase-conjugated goat anti-mouse antibody HRP-IgA (BioLegend) (100 μL / well, diluted with serum diluent at 1:2000 v / v) to the well plate and continue incubation for 1 hour. Subsequently, wash the plate 4 times with PBST and tap until there is no residual liquid in the well plate. Add 3,3',5,5'-tetramethylbenzidine (TMB) substrate (100 μL / well) and incubate for 15 minutes under light-proof conditions. Finally, add H2SO4 stop solution (100 μL / well) to stop the color reaction, and use a microplate reader to detect the absorbance (ODs, 450 nm).

[0092] The results are as follows Figures 6-7 As shown: The IgA secreted by the nasal mucosa and genital tract in the MnO2@COS@OVA+US group was significantly higher than that in the other four groups. This experiment shows that after ultrasound treatment, the vaccine preparation MnO2@COS@OVA can not only promote the secretion of IgA antibodies in mucosal immune sites, but also promote the secretion of IgA antibodies in distal mucosa, thereby enhancing the immune response of the systemic mucosal immune system.

[0093] (2) ELISA to measure the level of cytokines secreted by spleen cells

[0094] The spleen cell suspension was inoculated into a 12-well plate (5 × 10 5cells / well), and added antigen OVA solution (final concentration: 25μg / mL), and stimulated spleen cells for another 60h. Subsequently, the cell supernatant was collected, and the secretion levels of cytokines IFN-γ and IL-6 in the supernatant were detected by ELISA kit. Briefly, Capture Antibody solution (Thermo Fisher) (100μL / well) was added to the 96-well plate and coated overnight at 4°C. The next day, the plate was washed 4 times with PBST, 200μL Assay DiluentA solution was added, and incubated for 1h. Subsequently, the plate was washed 4 times with PBST, spleen cell supernatant (100μL / well) was added, and incubated for 2h. Subsequently, it was washed 4 times with PBST, and the plate was tapped until there was no residual liquid in the well. Then, 100μL HRP-labeled avidin (Avidin-HRP) solution was added to each well, incubated at 37°C for 1h, and the plate was washed 4 times with PBST. Next, 100 μL of TMB colorimetric solution was added to each well, and after color development for 15 min, H2SO4 solution (100 μL / well) was added to terminate the color development reaction. Finally, the OD value at 450 nm was detected by an ELISA reader.

[0095] The results are as follows Figures 8-9 As shown: the IFN-γ secreted by spleen cells induced by MnO2@COS@OVA+US group in vitro was higher than that of the other four groups, and the IL-6 secreted by spleen cells induced by MnO2@COS@OVA+US group in vitro was significantly higher than that of the other three groups (OVA, MnO2@COS@OVA and MnO2@COS@OVA-SC). This experiment shows that after ultrasonic treatment, MnO2@COS@OVA particles can induce good Th1 and Th2 immune responses.

[0096] In summary, the MnO2@COS prepared in the present invention can improve the antigen loading capacity of MnO2, and different vaccine preparations prepared with OVA are immunized in different treatment methods. The results show that ultrasonic treatment can promote the transmucus delivery of vaccine preparations and the penetration of the surface layer of the nasal mucosa, and ultrasonic treatment can promote the recruitment of dendritic cells (DCs) and macrophages in the nasal mucosal tissue. In particular, ultrasonic treatment significantly increased the level of secretory IgA antibodies in the nasal mucosa and genital mucosa of experimental mice. In addition, under the assistance of ultrasound, MnO2@COS@OVA particles can promote the secretion of cytokines (IFN-γ and IL-6) by splenocytes in vitro. This is mainly due to the ability of ultrasound to promote the penetration of vaccine preparations into the surface layer of the nasal mucosa and induce a stronger mucosal immune response. In short, the ultrasound-assisted manganese dioxide vaccine delivery system has the potential to be applied to mucosal vaccine delivery systems.

[0097] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. An application of an ultrasound-assisted manganese dioxide vaccine delivery system in the preparation of a mucosal vaccine preparation, characterized in that: The ultrasound-assisted manganese dioxide vaccine delivery system is obtained by coating hollow mesoporous manganese dioxide nanospheres with chitosan oligosaccharide and loading ovalbumin, and specifically comprises the following steps: (1) adding tetraethyl orthosilicate, concentrated ammonia water and anhydrous ethanol to water, stirring to react, collecting the precipitate by centrifugation after the reaction is completed, washing and freeze-drying to obtain SiO2 nanoparticles; (2) Ultrasonic mixing of potassium permanganate aqueous solution and SiO2 nanoparticles, followed by stirring for reaction, and after the reaction is completed, centrifugation to collect the precipitate, washing it, and resuspending it in water to obtain a mesoporous MnO2-coated SiO2 suspension; (3) adding the mesoporous MnO2-coated SiO2 suspension to the Na2CO3 aqueous solution, stirring the reaction at 60±5°C, collecting the precipitate by centrifugation after the reaction is completed, washing, and freeze-drying to obtain hollow mesoporous MnO2 nanoparticles; (4) Ultrasonic mixing of the hollow mesoporous MnO2 nanoparticles and the chitosan oligosaccharide solution, followed by stirring for reaction, and after the reaction is completed, centrifugation to collect the precipitate, washing it, and resuspending it in water to obtain a MnO2@COS suspension; (5) mixing the MnO2@COS suspension and the ovalbumin solution and incubating them at room temperature for 3 to 6 hours to obtain the vaccine preparation MnO2@COS@OVA particles, i.e., the ultrasound-assisted manganese dioxide vaccine delivery system; The mucosal vaccine preparation is administered via nasal mucosa. The mucosal vaccine preparation requires ultrasonic treatment of the nasal cavity after administration.

2. The use according to claim 1, characterized in that: The chitosan oligosaccharide described in step (4) has a degree of polymerization of 2 to 20 and a molecular weight of ≤3200Da; The mass ratio of MnO2@COS to ovalbumin described in step (5) is 30-50:

3.

3. The use according to claim 2, characterized in that: The mass ratio of MnO2@COS to ovalbumin described in step (5) is 10:

1.

4. The use according to claim 1, characterized in that: The concentration of the concentrated ammonia water in step (1) is 28% by mass; The volume ratio of ethyl orthosilicate, concentrated aqueous ammonia, anhydrous ethanol and water in step (1) is 9:18:124:49; The amount of potassium permanganate used in step (2) is calculated based on 7.5 mg potassium permanganate per mg SiO2 nanoparticles; The amount of Na2CO3 used in step (3) is calculated based on the molar ratio of SiO2 to Na2CO3 in the reaction system being 1:10; The amount of chitosan oligosaccharide used in step (4) is calculated based on 1 mg of chitosan oligosaccharide per mg of hollow mesoporous MnO2 nanoparticles.

5. The use according to claim 1, characterized in that: The stirring reaction conditions in step (1) are: stirring at 400-600°C for 2-3 h; the ultrasonic conditions in steps (2) and (4) are: frequency 1 MHZ, power 6 W, time 5 minutes: work for 5 seconds and stop for 5 seconds; The stirring reaction conditions in step (2) are: stirring at 400-600°C for 5-8 h; The stirring reaction conditions in step (3) are: stirring at 100-200 rpm for 10-14 h; The stirring reaction conditions in step (4) are: stirring at 100-200 rpm for 1-3 h.

6. The use according to claim 1, characterized in that: The centrifugation conditions in steps (1), (2), (3) and (4) are: centrifugation at 8000-10000 rpm for 8-12 min; The washing in step (1) is performed by alternating washing with anhydrous ethanol and deionized water; The washing in steps (2) and (3) is performed using deionized water; The washing in step (4) is performed using deionized water.

7. The use according to claim 1, characterized in that: The ultrasound-assisted manganese dioxide vaccine delivery system can promote mucosal immune response; The mucosal immune response is a Th1 type immune response and / or a Th2 type immune response.

8. The use according to claim 1, characterized in that: The mucosal vaccine preparation needs to be ultrasonically treated in the nasal cavity after administration, and the ultrasound-assisted conditions are: frequency 1 MHZ, power 6W, time 5 minutes: work for 5 seconds and stop for 5 seconds.